Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.37 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19684988 | 0.92 | PDE4D (0.45) | DPP4PTGDR2ADORA1PDE4DACACB | |
| SCHEMBL19684706 | 0.89 | ADORA1 (0.42) | PTGDR2ADORA1PDE4DESR2P2RX3 | |
| SCHEMBL19684987 | 0.86 | ESR2 (0.42) | DPP4PTGDR2ADORA1PDE4DACACB | |
| SCHEMBL19684705 | 0.85 | MKNK1 (0.41) | DPP4PTGDR2ADORA1ESR2P2RX3 | |
| SCHEMBL19667110 | 0.84 | PTGDR2 (0.50) | PTGDR2P2RX3 | |
| SCHEMBL30207823 | 0.83 | ESR2 (0.45) | DPP4PTGDR2ADORA1ESR2GRAMD1A | |
| SCHEMBL19667380 | 0.83 | ESR2 (0.45) | DPP4PTGDR2ADORA1ESR2GRAMD1A | |
| SCHEMBL19684982 | 0.79 | PTGDR2 (0.36) | DPP4PTGDR2ADORA1ACACBESR2 | |
| SCHEMBL19667497 | 0.77 | PTGDR2 (0.48) | PTGDR2P2RX3 | |
| SCHEMBL19667592 | 0.74 | ESR2 (0.45) | DPP4PTGDR2ADORA1PDE4DESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | DPP4 3218/4885PTGDR2 4262/4885ADORA1 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.